Viewing Study NCT02284932


Ignite Creation Date: 2025-12-24 @ 9:58 PM
Ignite Modification Date: 2025-12-28 @ 6:31 AM
Study NCT ID: NCT02284932
Status: UNKNOWN
Last Update Posted: 2016-09-08
First Post: 2014-10-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease
Sponsor: Laval University
Organization:

Study Overview

Official Title: Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease
Status: UNKNOWN
Status Verified Date: 2016-09
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Limb muscle dysfunction, characterized by atrophy and weakness, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality.

One prevailing hypothesis stipulates that the deterioration in muscle structure and function during COPD results from a spillover of inflammatory mediators from the lungs to the systemic circulation and then to the muscles.
Detailed Description: The investigators objective is to investigate the impact of COPD on key signaling pathways involved in the muscle atrophy. Moderate to severe COPD patients (FEV1 under 60% of predicted) and healthy controls will be recruited. All of the investigators patients will undergo a thorough baseline assessment in pulmonary capacity, muscle force and body composition. Blood sampling and biopsy of the quadriceps will be done. Key proteins of signaling intramuscular pathways involved in protein synthesis and degradation will be measured in the quadriceps.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: